Prime Medicine (PRME)

• Market cap: $382M
• 1 day: 0.69%
• 5 days: 5.43%
• 1 month: 3.56%
• 3 months: -33.41%
• 6 months: -46.31%
• Year to date: -2.68%
• 1 year: -56.57%
• 5 years: -81.07%
• 10 years: -81.07%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Employees: 234

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

816% more call options, than puts

Call options by funds: $2.28M | Put options by funds: $249K

9% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 34

0.3% less ownership

Funds ownership: 57.58% [Q2] → 57.28% (-0.3%) [Q3]

5% less funds holding

Funds holding: 122 [Q2] → 116 (-6) [Q3]

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

25% less capital invested

Capital invested by funds: $355M [Q2] → $266M (-$89.1M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 244% upside
• Avg. target: $13.25 355% upside
• High target: $18 519% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Silvan Tuerkcan 29% 1-year accuracy 16 / 56 met price target	244% upside $10	Market Outperform Initiated	10 Dec 2024
Guggenheim Debjit Chattopadhyay 21% 1-year accuracy 4 / 19 met price target	519% upside $18	Buy Reiterated	3 Dec 2024
Chardan Capital Geulah Livshits 8% 1-year accuracy 4 / 49 met price target	415% upside $15	Buy Maintained	13 Nov 2024
HC Wainwright & Co. Arthur He 0% 1-year accuracy 0 / 30 met price target	244% upside $10	Buy Reiterated	13 Nov 2024